PerkinElmer, Inc. Elects Robert F. Friel as Chief Executive Officer

VILLA GUARDIA, Italy--(BUSINESS WIRE)--Gentium S.p.A (the “Company”) announced today that the Data Safety Monitoring Board (DSMB) has initiated the planned interim analysis for the Company’s Phase III trial of Defibrotide to treat patients with severe veno-occlusive disease.

MORE ON THIS TOPIC